Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[225Ac]-FPI-1434 in advanced solid tumors
NCT03746431Phase 1Terminated
- Sponsor
- Fusion Pharmaceuticals Inc.
- Start
- Jan 2019
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of FPI-1434 in endometrial cancer (EC), Cervical Cancer (CC), ovarian cancer and 6 more (4 arms), sponsored by Fusion Pharmaceuticals Inc. Primary endpoints: Adverse Events at 1 year, Dose Limiting Toxicities at 6 weeks and 6 more. Started Jan 2019; status: terminated.
02
Drugs
FPI-1434
03
Conditions
endometrial cancer (EC)Cervical Cancer (CC)ovarian cancerbreast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03746431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746431.